Treatment | Auto-aggregation (%) | Hydrophobicity (%) | Injured cell (%) |
---|---|---|---|
Control | 5.89 ± 1.47*,a | 13.1 ± 2.16a | 16.52 ± 5a |
0.1 mg/ml GAE | 5.38 ± 1.61a | 9.87 ± 2.52ab | 26.84 ± 5.07ab |
0.1 mg/ml GAE + CFCS-Lc | 4.65 ± 2.7a | 8.28 ± 2.49bc | 41.4 ± 5.57bc |
0.1 mg/ml GAE + CFCS-Lc + CLA | 2.91 ± 1.52ab | 4.57 ± 2.06bc | 50.35 ± 3.93c |
0.5 mg/ml GAE | 4.45 ± 1.34a | 8.38 ± 1.98b | 36.33 ± 6.06b |
0.5 mg/ml GAE + CFCS-Lc | 3.41 ± 1.56a | 6.85 ± 1.77bc | 45.9 ± 4.77bc |
0.5 mg/ml GAE + CFCS-Lc + CLA | 2.18 ± 1.21b | 3.5 ± 1.2dc | 53.2 ± 7.01c |
1.0 mg/ml GAE | 3.69 ± 0.86a | 6.36 ± 1.74bc | 45.34 ± 5.42bc |
1.0 mg/ml GAE + CFCS-Lc | 2.78 ± 1.41b | 4.8 ± 1.54c | 49.92 ± 6.47bc |
1.0 mg/ml GAE + CFCS-Lc + CLA | 1.45 ± 0.02b | 2.89 ± 1.14c | 58.97 ± 3.45c |